Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsDaniel Jacoby, MD
Associate Professor AdjunctDownloadHi-Res Photo
About
Copy Link
Titles
Associate Professor Adjunct
Biography
Dr. Daniel Jacoby specializes in the diagnosis and treatment of heart failure and cardiomyopathy.
Dr. Jacoby is the Founder and Director of the premier Cardiomypathy Program in the region, dedicated to serving the needs of patients, and families, living with the diagnosis of cardiomyopathy. Expert diagnosis and treatment of hypertrophic, dilated, arrhythmogenic and restrictive cardiomyopathies, as well as evaluation for causes of sudden cardiac death, are available through the Cardiomyopathy Program.
Dr. Jacoby has contributed widely to the literature of both heart failure and cardiomyopathy.
He serves as the Clinical Director of Innovation for Yale New Haven Health System. In this role Dr. Jacoby provides clinically oriented leadership for mission aligned bio-tech for internal and external partnerships and investments.
Last Updated on July 15, 2024.
Appointments
Cardiovascular Medicine
Associate Professor AdjunctPrimary
Other Departments & Organizations
- Adult Congenital Heart Program
- All Institutions
- Cardiovascular Medicine
- Heart Transplant and Left Ventricular Assist Device Program
- Internal Medicine
- Yale Ventures
Education & Training
- Fellow
- Columbia Presbyterian Hospital (2007)
- Chief Fellow
- Columbia Presbyterian Hospital (2007)
- Resident
- Mount Sinai Hospital (2004)
- Chief Resident
- The Mount Sinai Hospital (2004)
- MD
- Yale School of Medicine (2000)
- BA
- Yale College, Judaic Studies (1993)
Research
Copy Link
Overview
Medical Research Interests
Amyloidosis; Clinical Trial; Genetics; Heart Failure; Heart Transplantation; Sleep
ORCID
0000-0002-9182-275X
Research at a Glance
Yale Co-Authors
Frequent collaborators of Daniel Jacoby's published research.
Publications Timeline
A big-picture view of Daniel Jacoby's research output by year.
Research Interests
Research topics Daniel Jacoby is interested in exploring.
Sangchoon Jeon, PhD
Tariq Ahmad, MD, MPH
Christopher Maulion, MD
Edward J Miller, MD, PhD
Nancy Schmieder Redeker, RN, MSN, PhD, FAHA, FAAN
Harlan Krumholz, MD, SM
109Publications
6,661Citations
Heart Failure
Heart Transplantation
Sleep
Amyloidosis
Publications
2026
Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study
Tower-Rader A, Masri A, Nassif M, Abraham T, Barriales-Villa R, Choudhury L, Cooper R, Elliott P, Maron M, Olivotto I, Oreziak A, Owens A, Solomon S, Heitner S, Jacoby D, Kupfer S, Liu X, Malik F, Melloni C, Simkins T, Wei J, Saberi S. Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study. European Heart Journal 2026, ehaf1085. PMID: 41780565, DOI: 10.1093/eurheartj/ehaf1085.Peer-Reviewed Original ResearchCitationsAltmetricConceptsTreatment-emergent serious adverse eventsSymptomatic obstructive hypertrophic cardiomyopathyNew-onset atrial fibrillationLeft ventricular ejection fractionObstructive hypertrophic cardiomyopathyObstructive HCMHypertrophic cardiomyopathyAtrial fibrillationKansas City Cardiomyopathy Questionnaire-Clinical Summary ScoreIncidence of new-onset atrial fibrillationNYHA class improvementOutflow tract gradientMedian Follow-UpOpen-label studyVentricular ejection fractionCardiac myosin inhibitorSerious adverse eventsClinical responseEjection fractionAficamtenIschemic colitisNo deathsAdverse eventsHeart failureFollow-upEfficacy of aficamten according to geographic location of patients with hypertrophic obstructive cardiomyopathy.
Coats C, Abraham T, Barriales-Villa R, Arad M, Cardim N, Claggett B, Düngen H, Garcia-Pavia P, Hagège A, Kulac I, Ma C, Maron M, Masri A, Merkely B, Michels M, Oreziak A, Solomon S, Tfelt-Hansen J, Jacoby D, Heitner S, Kupfer S, Olivotto I. Efficacy of aficamten according to geographic location of patients with hypertrophic obstructive cardiomyopathy. ESC Heart Failure 2026 PMID: 41711247, DOI: 10.1093/eschf/xvag023.Peer-Reviewed Original ResearchAltmetricConceptsObstructive HCMBaseline characteristicsSecondary endpointsKansas City Cardiomyopathy Questionnaire clinical summary scoreLeft ventricular ejection fraction <Left ventricular outflow gradientBaseline characteristics of patientsHypertrophic obstructive cardiomyopathyEjection fraction <Higher Body Mass IndexCardiac myosin inhibitorClinical summary scoreSerious adverse eventsCharacteristics of patientsBody mass indexTreatment effectsKCCQ-CSSOutflow gradientObstructive cardiomyopathyPeak oxygen uptakeAficamtenTreatment responseAdverse eventsMass indexExercise capacity
2025
Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCM
Kaski J, Kantor P, Nakano S, Olivotto I, Russell M, Godown J, Chiu M, German P, Heitner S, Jacoby D, Kupfer S, Lutz J, Maharao N, Malik F, Melloni C, Morales P, Simkins T, Wei J, Ho C, Investigators O. Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCM. Circulation Heart Failure 2025, 19: e013418. PMID: 41347307, PMCID: PMC12908643, DOI: 10.1161/circheartfailure.125.013418.Peer-Reviewed Original ResearchCitationsAltmetricConceptsObstructive hypertrophic cardiomyopathyOutflow tract gradientOpen-label extensionHypertrophic cardiomyopathyResting left ventricular outflow tract gradientLong-term open-label extensionLeft ventricular outflow tract gradientNew York Heart Association functional classSymptomatic obstructive hypertrophic cardiomyopathyPlacebo-controlled trialSecondary end pointsBaseline to weekCardiac myosin inhibitorAssessment of pharmacokineticsYears of ageDose adjustmentDouble-blindAficamtenTreatment optionsCardiac biomarkersEnd pointsExercise capacityValsalvaFunctional classPediatric participantsEffect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy
Nassif M, Garcia-Pavia P, Masri A, Merkely B, Peña-Peña M, Barriales-Villa R, Bilen O, Burroughs M, Claggett B, Costabel J, de Barros Correia E, Dybro A, Elliott P, Lakdawala N, Lewis G, Mann A, Maron M, Miao Z, Nair A, Poulsen S, Reant P, Schulze P, Solomon S, Wang A, Sohn R, Berhane I, Heitner S, Jacoby D, Kupfer S, Malik F, Wohltman A, Fifer M, Spertus J, Investigators M. Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy. Journal Of The American College Of Cardiology 2025, 87: 1046-1058. PMID: 41493295, DOI: 10.1016/j.jacc.2025.10.059.Peer-Reviewed Original ResearchCitationsAltmetricConceptsPatients' health statusHealth statusSummary scoreObstructive hypertrophic cardiomyopathySeattle Angina Questionnaire summary scorePatient-reported health statusSymptomatic obstructive hypertrophic cardiomyopathyHealth status of patientsPhysical limitation scaleKCCQ overall summary scoresHealth status scoresIndividual participants’ experience.Within-participant changesBaseline health status scoresKCCQ-OSSQuality of lifeQuestionnaire summary scoreOverall summary scorePatient's symptomsStatus of patientsParticipants' experiencesPrimary treatment goalHypertrophic cardiomyopathyIncremental benefitBaseline scoresAficamten in Obstructive Hypertrophic Cardiomyopathy A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial
Wang A, Garcia-Pavia P, Masri A, Merkely B, Nassif M, Peña-Peña M, Barriales-Villa R, Bilen O, Burroughs M, Claggett B, Costabel J, de Barros Correia E, Dybro A, Elliott P, Hegde S, Kulac I, Lakdawala N, Lewis G, Mann A, Nair A, Poulsen S, Reant P, Schulze P, Solomon S, Sohn R, Berhane I, Heitner S, Jacoby D, Kupfer S, Malik F, Wohltman A, Fifer M, Maron M, Investigators M. Aficamten in Obstructive Hypertrophic Cardiomyopathy A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial. Journal Of The American College Of Cardiology 2025, 87: 1029-1042. PMID: 41348072, DOI: 10.1016/j.jacc.2025.10.057.Peer-Reviewed Original ResearchCitationsAltmetricConceptsKansas City Cardiomyopathy Questionnaire-Clinical Summary ScoreObstructive hypertrophic cardiomyopathySymptomatic obstructive hypertrophic cardiomyopathyClinical responseHypertrophic cardiomyopathyLeft ventricular outflow tract gradientDisease burdenPatients treated with metoprololN-terminal pro-B-type natriuretic peptideLeft atrial volume indexPro-B-type natriuretic peptideNYHA functional class IIAssessment of clinical responsePatient-centred measuresOutflow tract gradientFunctional class IINYHA functional classAtrial volume indexFirst-line therapyEfficacy outcome measuresOutcome measuresClinically relevant outcome measuresPatient-level analysisPeak oxygen consumptionAssociated with greater benefitEffect of Aficamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCM
Wang X, Pabon M, Makuvire T, Maimaiti R, Abraham T, Barriales-Villa R, Claggett B, Coats C, Maron M, Masri A, Meder B, Nassif M, Olivotto I, Owens A, Saberi S, Jacoby D, Heitner S, Kupfer S, Malik F, Wohltman A, Solomon S, Hegde S. Effect of Aficamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCM. Circulation Heart Failure 2025, 19: e013918. PMID: 41205225, DOI: 10.1161/circheartfailure.125.013918.Peer-Reviewed Original ResearchAltmetricConceptsObstructive hypertrophic cardiomyopathyLV outflow tractSecondary end pointsNT-proBNPKCCQ-CSSE/e' ratioHypertrophic cardiomyopathyKansas City Cardiomyopathy Questionnaire clinical summary scoreLeft ventricular (LV) chamber sizeSubgroup analysisLV outflow tract gradientMethods:End pointsResults:Baseline health statusHigher LVOT gradientLateral E/e' ratioNT-proBNP levelsClinical summary scoreBeta-blocker useBaseline to endBurden of diseaseEnd of treatmentExercise modesLVOT gradientSafety and Efficacy of Aficamten in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A 96-Week Analysis From FOREST-HCM
Masri A, Sherrid M, Choudhury L, Garcia-Pavia P, Kramer C, Barriales-Villa R, Cooper R, Elliott P, Hegde S, Maron M, Nassif M, Oreziak A, Owens A, Solomon S, Tower-Rader A, Heitner S, Jacoby D, Kupfer S, Malik F, Melloni C, Simkins T, WEI J, Saberi S, Investigators F. Safety and Efficacy of Aficamten in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A 96-Week Analysis From FOREST-HCM. Journal Of Cardiac Failure 2025, 32: 533-537. PMID: 41027504, DOI: 10.1016/j.cardfail.2025.09.016.Peer-Reviewed Original ResearchCitationsAltmetricCharacterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial
Campain J, Griskowitz C, Newlands C, Claggett B, Kulac I, McGinnis S, Giverts I, Moreno F, Minasian A, Prasad C, Rupert L, Landsteiner I, Iskenderian N, Coats C, Lee M, Maron M, Owens A, Jacoby D, Heitner S, Kupfer S, Malik F, Wohltman A, Malhotra R, Lewis G. Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial. Circulation 2025, 152: 990-1002. PMID: 40910168, PMCID: PMC12493091, DOI: 10.1161/circulationaha.124.073585.Peer-Reviewed Original ResearchCitationsAltmetricConceptsCardiopulmonary exercise testingPeak VOObstructive hypertrophic cardiomyopathyLeft ventricular outflow tract gradientExercise testOutflow tract gradientCardiopulmonary exercise test protocolsExercise test protocolPrimary outcomeDisease-specific treatmentHypertrophic cardiomyopathyCardiac performanceCardiac functionTreatment of obstructive hypertrophic cardiomyopathySymptomatic obstructive hypertrophic cardiomyopathyLongitudinal measurementsHigh-sensitivity cardiac troponin IPeripheral oxygen extractionEvent-free survivalHeart failure hospitalizationHazard ratioAll-cause deathAdvanced heart failureReferral cohortCardiac troponin ILow incidence of atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy treated with aficamten: An analysis from the REDWOOD-HCM, SEQUOIA-HCM, and FOREST-HCM trials
Rowin E, Maron M, Olivotto I, Coats C, Abraham T, Nassif M, Barriales-Villa R, Saberi S, Heitner S, Jacoby D, Kupfer S, Malik F, Simkins T, Wei J, Masri A, REDWOOD-HCM S. Low incidence of atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy treated with aficamten: An analysis from the REDWOOD-HCM, SEQUOIA-HCM, and FOREST-HCM trials. Heart Rhythm 2025, 23: 212-214. PMID: 40897259, DOI: 10.1016/j.hrthm.2025.08.031.Peer-Reviewed Original ResearchCitationsAltmetricAficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy
Garcia-Pavia P, Maron M, Masri A, Merkely B, Nassif M, Peña-Peña M, Barriales-Villa R, Bilen O, Burroughs M, Claggett B, Costabel J, Correia E, Dybro A, Elliott P, Hegde S, Lakdawala N, Lewis G, Mann A, Miao Z, Nair A, Poulsen S, Reant P, Schulze P, Solomon S, Wang A, Sohn R, Berhane I, Heitner S, Jacoby D, Kupfer S, Malik F, Wohltman A, Fifer M. Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy. The New England Journal Of Medicine 2025, 393: 949-960. PMID: 40888697, DOI: 10.1056/nejmoa2504654.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsLeft ventricular outflow tract gradientSymptomatic obstructive hypertrophic cardiomyopathyOutflow tract gradientObstructive hypertrophic cardiomyopathyLeft atrial volume indexLeft ventricular mass indexAtrial volume indexVentricular mass indexHypertrophic cardiomyopathyPeak oxygen uptakeKCCQ-CSSMetoprolol monotherapyMetoprolol groupNT-proBNPValsalva maneuverBeta-blockersKansas City Cardiomyopathy Questionnaire clinical summary scoreMass indexN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideVolume indexDouble-dummy trialNT-proBNP levelsSecondary end pointsCardiac myosin inhibitor
Academic Achievements & Community Involvement
Copy Link
Activities
activity Section of Cardiovascular Disease Fellowship Training Program
2010 - PresentCommitteesMemberDetailsParticipate in candidate interview and selection processactivity Pediatric Cardiology Chief Search Committee
2011 - PresentCommitteesMemberDetailsReviewed candidate options. Interviewed candidates. Provided feedback and participated in debate and discussion in the selection of the Pediatric Cardiology Chief position.activity Quality Assurance and Process Improvement Committee Co-Chair
02/01/2014 - PresentCommitteesCo-ChairDetailsReview regulatory and quality metrics. Guide program through regulatory visits. Identify and improve on existing program structure for growth, quality, and efficiency. Solicit input from faculty and staff regarding program function. Establish metrics for dashboard population and review. Supervise development of internal metrics dashboard. Report out to Yale New Haven Transplant Center Quality Assessment and Process Improvement meeting.activity Advanced Heart Failure Recipient Review Committee Co-Chair
02/01/2014 - PresentCommitteesCo-ChairDetailsOrganize structure and process around recipient review for advanced heart failure therapies (left ventricular assist devices and heart transplant). Arbitrate and act as final decision maker with Co-Chair (Surgical Director of Advanced Heart Failure) regarding transplant listing and device implant decisions for patients brought up for consideration. Supervise nursing and coordinator staff in recipient evaluation. Review any and all issues that arise in the course of the week regarding transplant listed patients. Establish and maintain heart transplant and LVAD protocols and pathways.activity Clinical Operations Committee - Section of Cardiovascular Diseases
2018 - PresentCommitteesMemberDetailsRepresent the Comprehensive Heart Failure Program contributing to Cardiovascular Disease Section initiatives and clinical operations planning. Participate in Section vision and mission discussions particularly regarding clinical operations and contribute meaningful, actionable plans and perspectives to support and grow the Section of Cardiovascular Diseases on behalf of the faculty, staff, and patients we serve.
Honors
honor Teacher of the Year
05/01/2008Yale School of Medicine AwardYale New Haven Hospitalist ProgramDetailsUnited Stateshonor Humanism in Medicine
06/15/2004Other AwardAlpha Omega AlphaDetailsUnited States
News
Copy Link
Get In Touch
Copy Link